Eyconis

Executive Summary

Eyconis is a clinical-stage biotechnology company focused on developing long-acting therapies for major ophthalmic diseases, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA). The company leverages its exclusive worldwide license to Ascendis Pharma’s TransCon drug delivery technology, which enables sustained release of therapeutics, potentially reducing injection frequency and improving patient compliance. Eyconis aims to transform the standard of care for these chronic, vision-threatening conditions by creating best-in-class treatments with enhanced durability and safety profiles. Currently in Phase 1 clinical development, Eyconis is advancing its lead candidate, a long-acting formulation for wet AMD/DME. The company is privately held and has not disclosed recent financing details. Key near-term catalysts include the initiation of the Phase 1 trial, interim safety and tolerability data, and potential partnering discussions. Risks include early-stage clinical uncertainty, competitive landscape dominated by established anti-VEGF therapies, and reliance on TransCon technology platform. However, if successful, Eyconis’s products could capture significant market share in the large and growing ophthalmic sector.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 1 trial for lead candidate in wet AMD90% success
• Q4 2026Interim safety and tolerability data from Phase 170% success
• H2 2026Partnership or licensing deal for TransCon technology in ophthalmology40% success